✦ LIBER ✦

The efficacy of cerebrolysin in vascular dementia

✍ Scribed by M. Tapu; D. Bicu; F. Tapu; O. Stovicek

Book ID: 119303148
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 74 KB
Volume: 283
Category: Article
ISSN: 0022-510X
DOI: 10.1016/j.jns.2009.02.177

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cerebrolysin in vascular dementia: a ran

Cerebrolysin in vascular dementia: a randomized, placebo controlled study

✍ Philipp H. Novak; Herbert Moessler; Eugene I. Gusev; Alla B. Guekht 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 42 KB

Spotlight on Cerebrolysin in Dementia

✍ Plosker, Greg L.; Gauthier, Serge 📂 Article 📅 2010 🏛 Adis International Limited (now part of Wolters Kl 🌐 English ⚖ 106 KB

Cerebrolysin in Vascular Dementia: Impro

Cerebrolysin in Vascular Dementia: Improvement of Clinical Outcome in a Randomized, Double-Blind, Placebo-Controlled Multicenter Trial

✍ Alla B. Guekht; Herbert Moessler; Philipp H. Novak; Evgenyi I. Gusev 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 497 KB

P.4.006 Efficacy of cerebrolysin in alzh

P.4.006 Efficacy of cerebrolysin in alzheimer's disease

✍ S.I. Gavrilova; N.D. Selezneva; I.V. Kolykhalov; I.F. Roschina; G.A. Jarikov 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 146 KB

Efficacy of Yokukansan in the treatment

Efficacy of Yokukansan in the treatment of behavioral and psychological symptoms of dementia in patients with vascular dementia

✍ Nagata, Ken; Yamazaki, Takashi; Takano, Daiki; Masaki, Hisatsugu; Maeda, Tetsuya 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 40 KB

The long-term efficacy and tolerability

The long-term efficacy and tolerability of donepezil in patients with vascular dementia

✍ David Wilkinson; Gustavo Róman; Stephen Salloway; Jane Hecker; Karyn Boundy; Din 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 214 KB 👁 2 views

## Abstract ## Objective To determine the long‐term tolerability and efficacy of donepezil in patients with vascular dementia (VaD). ## Methods International, multicentre, open‐label, 30‐week extension study of two 24‐week, randomised, double‐blind, placebo‐controlled studies. Participants were